

Press Release



September 20, 2018
Stem Cell & Device Laboratory Co., Ltd.
<http://scad-kyoto.com/>

SCAD will present at the SPS Annual Meeting 2018 in Washington, DC, USA

SCAD will present a poster at the Safety Pharmacology Society (SPS) Annual Meeting 2018 to be held from September 30-October 3 in Washington, DC, USA. Our poster, titled

“3D-Cell Device with Aligned and Multilayered Myocardial Tissue Derived from iPS-Cells for Predictive Drug Safety Applications” (#0163),

features SCAD-MT™ cardiomyocyte, which is a promising platform for predictive, high-throughput *in vitro* toxicology and safety, and drug efficacy applications. We look forward to meeting you at the poster sessions.

General information

Official website: <https://www.safetypharmacology.org/AM2018/index.asp>

Date: September 30-October 3, 2018

Place: Marriott Wardman Park (2660 Woodley Rd NW, Washington, DC 20008 USA)

About SCAD

SCAD is an innovative biotech company offering cell product and service innovations that accelerate drug discovery and development through the convergence of nanotechnology, micro-engineering, and stem cell technologies. SCAD is committed to the development, manufacturing and commercialization of the next generation of cells and cell devices based on iPS cell technologies. SCAD's proprietary technologies in nanofiber-based cell culturing allow the creation of 3D, multilayered microtissues that closely recapitulate native tissues through increasing levels of maturity and functionality. Our initial offering is centered on the SCAD-MT™ cardiomyocyte, a myocardial microtissue, but other types of tissues are expected to come to market soon. As a company, we strive towards the realization of “a new society created by stem cells” by enabling the faster delivery of efficacious and safe medicines to patients.

For more information

Stem Cell & Device Laboratory, Inc. (SCAD)

Management Section: Mrs. Sonoko Chiaki

TEL: 075-744-1114; E-mail: scad.info@scad-kyoto.com